CSHEINEflornitina para Neuroblastoma de Alto Riesgo Post-Inmunoterapia

Fecha de inicio: 8 de abril de 2025

Inclusion Criteria: 1. According to the International Neuroblastoma Risk Group Classification, it has been histologically diagnosed as high-risk NB. 2. Under the age of 18. 3. The disease assessment status is PR (via CT or MRI) and the bone marrow smear is negative. 4. If the residual mass is MIBG negative or MIBG positive and lacks FDG-PET affinity, it is considered evidence that the mass does not represent active disease. Subjects with stable residual tumor mass visible on CT/MRI will be included in the study. 5. Qualified hematological parameters and organ function; Refer to the CI CTC 4.0 adverse reaction grading standard of grade 2 and below. 6. Eflornithine needs to be activated within 120 days after the completion of previous treatment. Exclusion Criteria: 1. According to the International Neuroblastoma Risk Group Classification, it has been histologically diagnosed as non high risk NB. 2. Prior to enrollment, the disease assessment status was either progressive disease (PD) or relapse (via CT or MRI). 3. Positive bone marrow smear. 4. Hematological parameters and organ function are not qualified, according to the CI CTC 4.0 adverse reaction grading standard of grade 3 or above. 5. The guardian does not agree to participate.